The Namibian medicines regulatory council is initiating a recall of Grand-Pa tablets and powders manufactured and marketed by GlaxoSmithKline. The recall is a result of the product failing stability studies at 30 degrees, which makes them unfit to be stored in Namibia’s climate zone. Ben Nangombe the Executive Director at the Ministry of Health and Social Services explains that these products may therefore not be imported nor used in Namibia until further communication from the office of the registrar of Medicines.